Ocular Systems' corneal graft delivery system reaches the US
This article was originally published in Clinica
Executive Summary
EndoSerter, a human corneal endothelium delivery instrument developed by Ocular Systems, has gained 510(k) clearance from the US FDA. The device delivers a corneal endothelial allograft measuring around 8.5mm in diameter and 175microns in central thickness through a single 4mm incision during endothelial keratoplasty procedures. Endothelial keratoplasty is a type of corneal transplantation that does not require a full-thickness graft. Endoserter is the first device to be cleared by the FDA for insertion of endothelial cells that restore corneal transparency, Winston-Salem, North Carolina-based Ocular Systems says. Each year approximately 18,000 patients in the US have endothelial cell replacement surgery.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.